Sumitomo Pharma - Public Comps and Valuation Multiples

Sumitomo Pharma Overview

About Sumitomo Pharma

Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Founded

1897

HQ

Employees

6.1K+

Website

sumitomo-pharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $2.7B

LTM EBITDA $594M

EV

$6.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sumitomo Pharma Financials

As of September 2025, Sumitomo Pharma reported last 12-month revenue of $2.7B and EBITDA of $594M.

In the same period, Sumitomo Pharma achieved $307M in LTM net income.

See Sumitomo Pharma valuation multiples based on analyst estimates

Sumitomo Pharma P&L

In the most recent fiscal year, Sumitomo Pharma reported revenue of $2.6B and EBITDA of $372M.

Sumitomo Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sumitomo Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.7B	XXX	$2.6B	XXX	XXX	XXX
Gross Profit	n/a	XXX	$1.6B	XXX	XXX	XXX
Gross Margin	n/a	XXX	62%	XXX	XXX	XXX
EBITDA	$594M	XXX	$372M	XXX	XXX	XXX
EBITDA Margin	22%	XXX	14%	XXX	XXX	XXX
EBIT	$436M	XXX	$195M	XXX	XXX	XXX
EBIT Margin	16%	XXX	7%	XXX	XXX	XXX
Net Profit	$307M	XXX	$155M	XXX	XXX	XXX
Net Margin	11%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	$1.9B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sumitomo Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.7B. EBITDA for the last twelve months was $594M. In the most recent fiscal year, Sumitomo Pharma achieved $2.6B in revenue and $372M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.7B	Analyst estimates available to subscribers	$2.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$1.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	61.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$594M	Analyst estimates available to subscribers	$372M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	22.1% EBITDA margin	Analyst estimates available to subscribers	14.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$436M	Analyst estimates available to subscribers	$195M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.2% EBIT margin	Analyst estimates available to subscribers	7.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$307M	Analyst estimates available to subscribers	$155M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.4% net profit margin	Analyst estimates available to subscribers	5.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$1.9B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sumitomo Pharma

This financial data table provides comprehensive performance metrics for Sumitomo Pharma, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sumitomo Pharma generated $2.7B in revenue over the last twelve months.
The company achieved $594M in EBITDA over the last twelve months.
Net income over the last twelve months reached $307M.

Fiscal Year Performance

In the most recent fiscal year, Sumitomo Pharma reported $2.6B in total revenue.
Fiscal year EBITDA was $372M.
The company maintained a gross profit margin of 61.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.2%.
Net profit margin reached 5.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sumitomo Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sumitomo Pharma Stock Performance

Sumitomo Pharma has current market cap of JPY 710B (or $4.7B), and EV of JPY 983B (or $6.5B).

Market Cap Evolution

Sumitomo Pharma Stock Data

As of October 17, 2025, Sumitomo Pharma's stock price is JPY 1788 (or $12).

See Sumitomo Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.5B	$4.7B	XXX	XXX	XXX	XXX	$0.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sumitomo Pharma Valuation Multiples

Sumitomo Pharma's trades at 2.6x EV/Revenue multiple, and -35.4x EV/EBITDA.

See valuation multiples for Sumitomo Pharma and 15K+ public comps

Sumitomo Pharma Financial Valuation Multiples

As of October 17, 2025, Sumitomo Pharma has market cap of $4.7B and EV of $6.5B.

Equity research analysts estimate Sumitomo Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sumitomo Pharma has a P/E ratio of 15.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.7B	XXX	$4.7B	XXX	XXX	XXX
EV (current)	$6.5B	XXX	$6.5B	XXX	XXX	XXX
EV/Revenue	2.4x	XXX	2.6x	XXX	XXX	XXX
EV/EBITDA	10.9x	XXX	-35.4x	XXX	XXX	XXX
EV/EBIT	14.8x	XXX	-14.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	15.2x	XXX	-11.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-15.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sumitomo Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sumitomo Pharma Margins & Growth Rates

Sumitomo Pharma's last 12 month revenue growth is 9%

Sumitomo Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Sumitomo Pharma's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sumitomo Pharma's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sumitomo Pharma and other 15K+ public comps

Sumitomo Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	22%	XXX	-7%	XXX	XXX	XXX
EBITDA Growth	20%	XXX	n/a	XXX	XXX	XXX
Rule of 40	2%	XXX	2%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	46%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	54%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial